Details for Patent: 8,017,150
Summary for Patent: 8,017,150
| Title: | Polyethylene oxide-based films and drug delivery systems made therefrom | ||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | ||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz | ||||||||||||||||||||||||||||||||||||||||
| Assignee: | Aquestive Therapeutics Inc | ||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/107,389 | ||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,017,150 | ||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Compound; | ||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | Scope and patent landscape for US Drug Patent 8,017,150: mucosally-adhesive water-soluble films for opioid analgesics using polyethylene oxide and hydrophilic cellulosic polymers United States Patent 8,017,150 is directed to a mucosally-adhesive, water-soluble oral film for delivery of an opioid analgesic active, using a polymer system that is overwhelmingly polyethylene oxide (PEO) with a capped fraction of a hydrophilic cellulosic polymer. The claim set defines (i) the polymer blend ratio and (ii) specific molecular-weight bands for low- and high-molecular-weight PEO fractions, plus (iii) optional commercial-type formulation attributes (viscosity, thickness, sweeteners, flavors, buffers, and additional actives). The scope is concentrated on formulation-specific constraints, not on the identity of the opioid, and it is therefore most relevant as a claim barrier to generic/authorized substitutes that preserve the same PEO/cellulosic composition architecture and similar physical film parameters. What is US Patent 8,017,150 claiming and what is the core invention?Short answer: It claims a mucosally-adhesive water-soluble film containing an opioid analgesic plus a specific PEO + hydrophilic cellulosic polymer system, with defined ratio limits and defined PEO molecular-weight bands. Claim 1: polymer composition and PEO molecular-weight architectureClaim 1 recites a film product comprising:
Practical claim meaning: For infringement analysis, the dispositive question is whether the accused film uses a PEO/cellulosic system where:
Dependent claims 2-3: physical film parameters tied to viscosity and thickness
These parameters are typical formulation guardrails that reduce design-around freedom by requiring a formulation whose bulk rheology and resulting film gauge land within the recited windows. Dependent claims 4-9: optional add-ins (additional actives, sweeteners, flavors, buffers)
These claims broaden coverage to finished products incorporating common film excipients, including two sweetener embodiments that read as specific preferred systems. What does claim 10 add or change versus claim 1?Claim 10 restates the film structure with the same overall concept but changes the polymer ratio constraint. Key difference: a broader upper bound on cellulosic fraction (up to about 4:1)Claim 10 requires:
Interpreting the wording in a formulation context:
Claim 10 still keeps:
Implication: Claim 10 likely provides an alternate way to satisfy the polymer blend constraints with an expressly different ratio articulation, strengthening enforceability against polymers that are close to—but structured differently than—the “>75% PEO / up to 25% cellulosic” formulation in claim 1. Where are the claim boundaries for design-around?US 8,017,150 is formulation-parameter heavy. The tightest boundaries are:
Design-around levers likely evaluated in validity/infringement disputes
How strong is the patent estate around this concept (and how do you map related IP)?You provided only the claim text. A complete patent landscape requires bibliographic data (publication numbers, priority date, assignees, prosecution history, and citations) and cannot be reliably constructed from claim text alone. Under the constraints of this task, no definitive landscape assertions about related patents, continuations, family members, or litigation can be made. What can be mapped from the claim structure itself: the claims target a narrow but commercially meaningful formulation “space” that is likely reused across product lines of oral mucosally-adhesive films and drug-in-film technologies. If multiple products exist in the same family (opioid film plus similar polymer matrix), related patents may concentrate on one or more of:
However, without identifying the patent family, assignee, and citation set from the actual record, no “how many patents cover” count or expiration timeline can be generated without risking incorrect business conclusions. What patents protect the same product concept across opioid films versus other mucosal films?Short answer: This patent protects opioid-containing mucosally-adhesive water-soluble films that use a specific PEO + hydrophilic cellulosic polymer system with defined MW fractions and dominance of PEO. Scope anchored on “opioid analgesic active”The opioid is described broadly as “an analgesic opiate pharmaceutical active.” That supports coverage across multiple opioid actives if incorporated into the claimed film matrix, assuming the accused product’s polymer system matches the claimed PEO/cellulosic constraints. Scope anchored on polymer system, not drug substanceEven if the opioid changes, the polymer architecture is still the gating limitation. For competitive intelligence, the most actionable infringement risk typically comes from competitors copying the same polymer blending strategy rather than from swapping the opioid. How does the polymer MW definition affect infringement and claim construction?This patent’s novelty is framed through specific PEO molecular-weight windows and low-MW proportion. Potential infringement evidence needed (conceptually)In disputes, polymer MW distribution is the key technical fact:
What “about” signals for enforcementThe claims use “about” in several ranges:
This typically widens interpretive flexibility, so a competitor trying to avoid infringement by inching the values near boundaries may not succeed if their formulation still falls within the practical meaning of “about” ranges. How do the dependent claims expand coverage to real-world formulations?The dependent claims (4-9, 13-18) broaden claim coverage to typical finished-product variations. What is explicitly covered
What is not specified in the claim text you provided
So, the patent is not limited to a single opioid identity in the claim language you provided, but is limited to the polymer blend concept as stated. When does US 8,017,150 lose exclusivity?No expiration/exclusivity date can be stated from claim text alone. Patent term depends on:
Key claim map (for fast infringement screening)
Key Takeaways
FAQs
References
More… ↓ |
Drugs Protected by US Patent 8,017,150
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,017,150
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 077803 | ⤷ Start Trial | |||
| Austria | 536868 | ⤷ Start Trial | |||
| Austria | 536869 | ⤷ Start Trial | |||
| Austria | 553746 | ⤷ Start Trial | |||
| Australia | 2002332118 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
